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incidence and epidemiology
The incidence of chronic myeloid leukemia (CML) ranges
between 10 and 15 cases/106/year (age adjusted) without any
major geographic or ethnic differences [1]. The median age at
diagnosis ranges between 60 and 65 years in Europe, but is
considerably lower in countries where the population is
younger. The prevalence of CML is steadily rising due to the
very substantial prolongation of survival that has been achieved
with targeted therapy [2].
molecular biology and pathology
The translocation of the ABL gene from chromosome 9 to 22 t
(9;22)(q3.4;q1.1) leads to the formation of a new, hybrid,
fusion gene (BCR-ABL) that codes for an oncoprotein (P210,
more rarely P190 or P230) that is located in the cytoplasm and
has a strong, constitutively activated, tyrosine kinase activity,
resulting in the activation of several downstream signals that
transform hematopoietic stem cells [3]. BCR-ABL-positive cells
are genetically unstable and are prone to develop multiple and
heterogenous genomic abnormalities, resulting in the
transformation of the leukemic phenotype from chronic to
acute, hence leading to the progression from chronic (CP) to
accelerated and blast phases (AP, BP) [1]. One important event
associated with progression is the development of point
mutations in the kinase domain (KD) of the BCR-ABL gene,
leading to resistance to the tyrosine kinase inhibitors (TKI) [4,
5].
Bone marrow (BM) biopsies taken from untreated patients at
diagnosis [6] show increased cellularity due to proliferation of
the granulocytic series that turns in different stages of
maturation, although myelocytes and segmented forms
predominate. No substantial features of dysplasia are found.
Eosinophils may be prominent. Blasts must account for <5% of
the whole examined population. Megakaryocytes are smaller
than normal with hypolobulated nuclei (‘dwarf
megakaryocytes’). Although their number may be normal or
slightly decreased, in ∼50% of cases there is moderate to
extensive megakaryocytic proliferation. Moderate to marked
reticulin ﬁbrosis is encountered in ∼30% of cases [6]. Pseudo-
Gaucher cells and sea-blue histiocytes are usually observed.
Notably, the BM picture undergoes important changes,
particularly following long-term treatment. These consist in
reduction of the granulocytic cellularity, normalization of
megakaryopoiesis, regression of ﬁbrosis, and increase in
apoptosis associated with decrease in proliferative activity.
The recognition of disease progression from CP to BP is
relevant for prognosis and treatment. However, the clinical and
morphologic boundaries between these stages are sometimes
vague. Immunohistochemistry with a large panel of antibodies
raised against CD34, TdT, myeloid, monocytic, erythroid, B
and T-lymphoid cell markers gives objective support to the
morphologic interpretation, by also allowing the distinction
between myeloid (70%–80%) and lymphoid (20%–30%) blast
crisis [6].
diagnosis/assessment of prognosis
The symptoms are not speciﬁc, including weight loss, asthenia,
small fever, sweats, and malaise, and are not frequent, since in
∼40% of cases the diagnosis is fortuitous, being based on
abnormal blood counts and differential. Physical ﬁndings
consist mainly or only in splenomegaly, in slightly >50% of
patients. The hallmark of diagnosis is leukocytosis with
basophilia and with immature granulocytes, mainly
metamyelocytes, myelocytes and promyelocytes, and few or
occasional myeloblasts. Severe anemia is rare. Thrombocytosis
is frequent. Blood counts and differential are very important
for the calculation of a prognostic risk (Table 1) [7–9] and for
the distinction between chronic, accelerated and blast phases
(Table 2) [6, 10, 11].
The diagnosis must be conﬁrmed by cytogenetics showing t
(9; 22)(q3.4;q1.1), and by reverse transcriptase polymerase
chain reaction (RT-PCR) showing BCR-ABL transcripts.
Cytogenetics must be performed by chromosome banding
analysis (CBA) of marrow cell metaphases [12, 13]. If marrow
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cells cannot be obtained, CBA can be substituted by interphase
ﬂuorescence in situ hybridization (I-FISH) of blood cells, using
dual color dual fusion probes that allow the detection of BCR-
ABL+ nuclei. CBA is required, because it is necessary to detect
additional chromosome abnormalities. FISH is not required,
but it may become necessary to detect some variant
translocations [14]. Qualitative RT-PCR is performed on RNA
extracted by freshly collected BM or blood cells. It identiﬁes
the transcript type, either e14a2 or 13a2 (also known as b3a2
and b2a2), or much more rarely e19a2, or e1a2, indicating the
BCR-ABL protein weight (P210, rarely P230 or P190). Real
time, quantitative, PCR (RT-Q-PCR measuring BCR-ABL
transcripts level as BCR-ABL % on the International Scale) is
not required baseline. It will be necessary, later on, for
monitoring the response to treatment [15–17]. These
recommendations for the baseline diagnostic work-up are
summarized in Table 3.
management, treatment, and monitoring
The treatment of CML was historically based on busulfan, that
should no longer be used, then on hydroxyurea, that is still
used for a short and quick pretreatment phase in case of
marked leukocytosis or thrombocytosis [1]. Interferon-α
(IFNα) became the gold standard in the 90s and for a decade,
before the introduction of tyrosine kinase inhibitors (TKI)
[18]. Imatinib was the ﬁrst TKI to be used and is still the gold
standard of ﬁrst-line treatment worldwide [19–24]. More
recently, the second-generation TKI nilotinib and dasatinib
have been tested and approved for second-line [25, 26], then
also for ﬁrst-line treatment [27–31]. Current treatment
recommendations are reported in Table 4.
These recommendations are based on the assessment of the
response (Table 5) and on the deﬁnition of the response
(Table 6). The response to TKI can be classiﬁed as optimal,
Table 2. Clinical and hematologic criteria for the deﬁnition of AP and BP according to WHO [6] and to ELN [11]
Accelerated phase Blast phase
WHO [6] ELN [11] WHO [6] ELN [11]
Spleen Persisting or increasing splenomegaly unresponsive to therapy / / /
WBC Persisting or increasing WBC (>10 × 109/l) unresponsive to therapy / / /
Blast cellsa 10%–19% 15%–29% ≥20% ≥30%
Basophilsa >20% >20% / /
Platelet count >1000 × 109/l uncontrolled by therapy / / /
<100 × 109/l unrelated to therapy Yes / /
CCA/Ph+ Present Present / /
Extramedullary involvementb / / Present Present
The criteria of AP are different, reﬂecting the difﬁculty of making the diagnosis of this transitory phase. The criteria of BP differ only for the percent of blast
cells. Only one of the listed criteria is sufﬁcient for the diagnosis of AP or BP.
CCA/Ph+ = clonal chromosome abnormalities in Ph+ cells.
aIn peripheral blood or in BM.
bExcluding liver and spleen, including lymph nodes, skin, CNS, bone, and lung.
AP: accelerated phase; BP: blast phase; WHO: World Health Organization; ELN: European LeukemiaNet; BM: bone marrow.
Table 1. The relative risk of a patient with CML can be calculated using simple clinical and hematologic data provided that they are collected prior to any
treatment
Sokal et al. [7] EURO [8] EUTOS [9]
Age (years) 0.116 (age—43.4) 0.666 when age >50 NA
Spleen size (cm) 0.345 × (spleen—7.51) 0.042 × spleen 4 × spleen
Platelet count (×109/l) 0.188 × [(platelet/700)2− 0.563] 1.0956 when platelet ≥1500 NA
Blood blast cells (%) 0.887 × (blast cells—2.10) 0.0584 × blast cells NA
Blood basophils (%) NA 0.20399 when basophils >3% 7 × basophils
Blood eosinophils (%) NA 0.0413 × eosinophils NA
Relative risk Exponential of the total total × 1000 Total
Low <0.8 ≤780 ≥87
Intermediate 0.8–1.2 781–1480 NA
High >1.2 >1480 >87
There are three systems: Sokal et al. [7], that was developed in 1984, in the era of conventional chemotherapy; EURO [8], that was derived in 1998 from
IFNα-treated patients, and EUTOS [9], that has derived more recently (2011) from imatinib-treated patients. The EUTOS risk score is simpler, and in
imatinib-treated patients have a prognostic value greater than Sokal and EURO.
Spleen is measured by manual palpation and expressed as maximum distance below costal margin.
NA: not applicable; CML: chronic myeloid leukemia; IFNα: interferon-α.
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meaning that continuing treatment the survival is predicted to
be normal or close to normal; and failure, meaning that
treatment must be switched to a second-generation TKI, or
allogeneic hematopoietic stem cell transplantation (alloHSCT).
Between optimal and failure, there is a gray zone that was
Table 4. Treatment recommendations
Chronic phase
First line Imatinib 400 mg, or nilotinib 300 mg × 2, or dasatinib
100 mg
Second line In case of intolerance, switch to another TKI, taking into
consideration the side effects of the ﬁrst TKI, and
comorbidities
In case of failure of imatinib, switch to nilotinib, or
dasatinib, taking into consideration the presence and
the type of BCR-ABL KD mutation
In case of failure of nilotinib or dasatinib, switch to
dasatinib or nilotinib, taking into consideration the
presence and the type of BCR-ABL KD mutation.
Consider alloHSCT
Third line In case of failure of two or three TKI, consider alloHSC
Accelerated/blastic phase
TKI naïve Imatinib 600 or 800 mg, or nilotinib 400 mg × 2 or
dasatinib 140 mg, and consider alloHSCT
TKI
pretreated
Switch to another TKI, consider chemotherapy and
alloHSCT
For all recommendations for CP, the level of evidence is I (evidence from at
least one large randomized, controlled trial of good methodological quality)
and the grade is A (strong evidence for efﬁcacy with a substantial clinical
beneﬁt, strongly recommended). However, the choice among the three
currently available tyrosine kinase inhibitors (TKI) is based on a low level
of evidence, which does not allow any strong recommendation to be made.
For all recommendations for AP and BP, the level of evidence is III/IV
(prospective and retrospective cohort studies) and the grade is B (strong or
moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally
recommended). Experimental treatments are under active investigation in
ﬁrst, second, and third lines.
TKI: tyrosine kinase inhibitors; alloHSCT: allogeneic hematopoietic stem
cell transplantation; KD: kinase domain.
Table 3. Recommendations for the diagnostic workup and for assessing and monitoring the response to treatment
Baseline (diagnostic
workup)
To assess the response To monitor the response and the treatment
Blood counts and differential Yes Every 15 days until a CHR has been
achieved
Every 3 months
Bone marrow, cytology Yes No No
Bone marrow, Karyotype
(CBA)
Yes At 3 and 6 months, then every 6
months, until a CCgR has been
achieved
Every 12 months, once a CCgR has been achieved, only
if molecular response cannot be assured
Blood, I-FISH No No Only if CBA of marrow cell metaphases cannot be
performed, and molecular response cannot be assessed




No Every 3 months until a major molecular
response has been achieved
Every 6 months, once a MMR has been achieved
Mutational analysis Only in AP or BP No Only in case of failure (see Table 6)
There are no prospective studies providing evidence for these recommendations, but they are strongly supported by expert opinions and by the design of all
main studies [1, 6, 10, 11, 14, 15, 16, 19–32, 36–39].
CBA: chromosome banding analysis; I-FISH: interphase ﬂuorescence in situ hybridization; CCgR: complete cytogenetic response; CHR: complete
hematologic response; AP: accelerated phase; BP: blastic phase; RT-PCR: reverse transcriptase polymerase chain reaction; RT-Q-PCR: quantitative reverse
transcriptase polymerase chain reaction; MMR: major molecular response.
Table 5. Assessment of responses
CHR
WBC <10 × 109/l, no immature granulocytes, basophils <5%, platelet
count <450 × 109/l, spleen non-palpable
CgR
Complete CgR, no Ph+ metaphases by CBA, or <1% BCR-ABL+ nuclei
by I-FISH
Partial CgR, 1%–35% Ph+ metaphases by CBA
Minor CgR, 36%–65% Ph+ metaphases by CBA
Minimal CgR, 66%–95% Ph+ metaphases by CBA
No CgR, >95% Ph+ metaphases by CBA
MR
Major MMR when the BCR-ABL transcript level is ≤0.1% on the
International Scale
Complete MR when the BCR-ABL is undetectable by RT-Q-PCR. The
transcript level can be below 0.01% or 0.0032%, or 0.001%, depending
on the sensitivity of the assay
The CgR is assessed on marrow cells by standard CBA. The molecular
response is assessed on blood, buffy coat, cells, by RT-Q-PCR and is
expressed as BCR-ABLIS % according to the International Scale. The
deﬁnition of these responses is based on expert consensus [1, 6, 10, 11].
CHR: complete hematologic response; WBC: white blood cell; CgR:
cytogenetic response; CBA: chromosome banding analysis; I-FISH:
interphase ﬂuorescence in situ hybridization; MR: molecular response;
MMR: major molecular response.
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deﬁned ‘suboptimal’ [10, 11]. Now the term suboptimal may
be better replaced by the term ‘warning’, meaning that the
response must be monitored more carefully and that the
patient may be eligible for potentially better treatments.
The choice of the treatment, particularly the decision of
moving from one treatment to another, strongly depends on
the response to treatment, particularly on the degree of the
cytogenetic response (CgR), and on the detection of BCR-ABL
KD point mutations [32].
cytogenetic monitoring
Cytogenetic monitoring (Table 3) must be performed by CBA
of marrow cell metaphases, reporting the number of Ph+
metaphases relative to the number of metaphases analyzed,
that must be at least 20 [10, 11, 32]. The CgR is deﬁned
complete (CCgR) with 0% Ph+ metaphases, partial (PCgR)
with 1%–35% Ph+ metaphases, minor with 36%–65% Ph+
metaphases, minimal with 66%–95% Ph+ metaphases, and
none if >95% of metaphases are Ph+ [10, 11]. I-FISH can
substitute for CBA if marrow cells cannot be sampled or if a
sufﬁcient number (20) of marrow cell metaphases cannot be
evaluated [11, 14]. However, based on I-FISH, one cannot
assess the degree of CgR, (minimal, minor, partial) but can
establish only if the CgR is complete (<1% BCR-ABL+ nuclei
out of at least 200 nuclei) [14]. The CgR must be assessed at 3
and 6 months, then at least every 6 months, until a CCgR has
been achieved, then at least every 12 months, unless a regular
molecular monitoring cannot be assured [11].
molecular monitoring
A quantiﬁcation of BCR-ABL mRNA, performing RT-Q-PCR
from 20 ml EDTA-anticoagulated peripheral blood, is required
every 3 months (Table 3). This method represents the most
sensitive tool for the assessment of the disease status,
particularly of minimal residual disease [11]. BCR-ABL
transcript levels should be expressed according to the
International Scale (BCR-ABLIS %) [15] to guarantee
comparability of results among different laboratories.
Therefore, local methods require thorough optimization and
harmonization with reference laboratories [16, 17]. Intervals
can be prolonged from 3 to 6 months after repeated
achievement of a major molecular response (BCR-ABLIS
≤0.1%, 3 log reduction from standardized baseline). Signiﬁcant
rises of BCR-ABL transcript levels (5–10 fold beyond major
molecular response, MMR) during long-term therapy are early
indicators for treatment failure or non-adherence. The
achievement of very deep molecular responses (4–5 log
reduction) during TKI treatment is the prerequisite for therapy
interruptions within controlled trials [33].
More than 90 different point mutations in the KD of BCR-
ABL that impair TKI binding have been reported in patients
who develop resistance to imatinib [4, 5, 34]. Importantly, only
a small, deﬁnite subset of them retains insensitivity also to
dasatinib and/or nilotinib. In particular, V299L, T315A, and
F317L/V/I/C are resistant to dasatinib. Y253H, E255K/V, and
F359V/C/I are resistant to nilotinib [34–36]. T315I is resistant
to both nilotinib and dasatinib. Although mutations account
for <50% of failures, the knowledge of BCR-ABL mutation
status is a valuable piece of information to be integrated in the
decision algorithm aimed at tailoring the best therapeutic
strategy for each TKI-resistant patient. Recommendations as to
when mutation analysis should be performed have recently
been compiled by European LeukemiaNet (ELN) [34] and are
reported below:
• During ﬁrst-line therapy with imatinib, the analysis is due in
case of failure and in case of an increase in BCR-ABL
transcript levels leading to a loss of major molecular
response.
• During second-line therapy with dasatinib or nilotinib, the
analysis is due in case of hematologic or cytogenetic failure.
• In case of AP or BP, the mutational analysis is always due.
In any case, mutation analysis should be performed by direct
sequencing. More sensitive strategies should remain conﬁned
to a research area.
discussion and conclusions
These guidelines are based on a number of high quality reports
of phase 2 and phase 3 studies, single-arm, and randomized,
that have been published in peer-reviewed journals over the
last 10 years [19–31, 36–39], and on the recommendations that
were shared by an expert panel that was appointed by ELN [10,
11]. The deﬁnition of the responses, and the guidelines for
monitoring the response to treatment, are not based on studies
that were speciﬁcally designed for these purposes, but reﬂect
Table 6. Deﬁnition of the response to ﬁrst-line therapy with TKI (imatinib, nilotinib, and dasatinib)
Optimal = continue the treatment Warning =monitor more carefully
some patients may beneﬁt of a change of treatment
Failure = change the treatment
3 months Ph+ ≤95%, or BCR-ABL <10% Ph+ >95%, or BCR-ABL >10%
6 months Ph+ ≤35%, or BCR-ABL <10% Ph+ 35%–65% Ph+ >65%, or BCR-ABL >10%
12 months Ph+ 0, or BCR-ABL ≤1% Ph+ ≥1%, or BCR-ABL >1%
Any time Loss of MMR Loss of CHR loss of CCgR, mutations
These deﬁnitions are a provisional adaptation of the original ELN deﬁnitions of the response to ﬁrst-line therapy with imatinib [11]. Operationally, ‘optimal’
means to continue the treatment, ‘failure’ to change the treatment, and ‘warning’ to monitor more carefully and to be ready to consider a change of
treatment.
TKI: tyrosine kinase inhibitors; MMR: major molecular response; CHR: complete hematologic response; CCgR: complete cytogenetic response; ELN:
European LeukemiaNet.
Annals of Oncology clinical practice guidelines
Volume 23 | Supplement 7 | October 2012 doi:10.1093/annonc/mds228 | vii
expert opinions [1, 10, 11, 14–17, 32, 34], and the design of
almost all the important clinical trials [19–31, 36–39].
For treatment and recommendations for CP, the evidence is
always based on at least one large randomized, controlled trial,
or a phase 2 single-arm study of good methodologic quality,
providing strong evidence for efﬁcacy with a substantial clinical
beneﬁt (level of evidence I, grade A). However, there is not yet
sufﬁcient evidence to make speciﬁc recommendations on
which TKI should be used ﬁrst line. For treatment
recommendations in AP and BP [1, 10, 11, 35], the level of
evidence is lower, III/IV, based mainly on phase 2 single-arm
studies and retrospective analysis, so that the grade B is also
lower (moderate evidence for efﬁcacy, with a limited clinical
beneﬁt, generally recommended).
Overall, based on the three TKI that are currently available,
the progression-free survival is projected at 80%–90%, and
overall survival at 85%–95%, after >5 years, with a tendency to
a true plateau. The use of second-generation TKI front-line has
the potential of reducing the rate of progression to AP and BP.
AlloHSCT has the potential to cure, but is currently limited to
the patients who are resistant to TKI [35]. The combination of
TKI with IFNα [24, 36–38], as well as the use of other second-
or third-generation TKI, like bosutinib [39], that has an
efﬁcacy proﬁle similar to nilotinib and dasatinib, or ponatinib
[40], that is active also in case of T315I mutation, are still
investigational.
The gold standard of ﬁrst-line treatment is still imatinib,
400 mg daily (Table 5). In this setting, the choice of a higher
dose of imatinib (600 or 800 mg daily) or of a second-
generation TKI must be balanced between ‘pros’ (more
potency, more rapid response, deeper molecular response) and
‘cons’ (shorter period of observation, higher cost). For second-
line treatment, the choice can be guided by the type of the
adverse events which caused the switch, and by the results of
mutational analysis. However, these choices are based on a low
level of evidence. The treatment of accelerated and blast phase
is still orphan. Switching to other TKI, using chemotherapy or
testing investigational treatments are all of limited help.
AlloHSCT is still the most valid option, but it should be
offered before the disease has become blastic [1].
The goal of the treatment is to prevent progression, so as to
ensure a normal survival. For that goal, TKI treatment should
be continued indeﬁnitely. However, there are data suggesting
that in the patients where the disease is no longer molecularly
detectable (so-called complete molecular remission), the
treatment can be safely discontinued [33]. The number of these
patients is small, but is predicted to increase with the use of
second-generation TKI. Treatment discontinuation, that is
particularly important for the quality of life [41], is an
important achievement and will probably become the major
and more important end point of next clinical studies.
Progress in treatment of CML has been such that the disease
should no longer be considered fatal and incurable, as it was
for more than one century. The very name of leukemia could
be now disputed, because leukemia is still synonymous with
fatality for the public. This great success has a price, including
not only the cost of the treatment, and of monitoring, but also
the availability of well trained, fully dedicated medical
personnel with the capacity of understanding and solving the
problems of this rare disease, of interpretating the results of
sophisticated laboratory techniques, of managing very
expensive drugs, and of interacting with the patients, who must
be aware of all the aspects of the disease and its treatment,
from the potential of a fatal outcome to the potential of cure,
and must be assisted in all aspects of family and social life.
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